FDA medtech regulators reportedly among latest Trump layoffs
https://www.massdevice.com/fda-medtech-r...p-layoffs/
"FDA firings have an interesting relation to Musk’s Neuralink
Reuters reports that the FDA cuts extended to some agency employees reviewing Elon Musk’s Neuralink brain-computer interface (BCI) company.
The report said the firings included around 20 people in the FDA’s office of Neurological and Physical Medicine Devices. Several of those employees worked on Neuralink and other BCI devices, the report said, citing two sources with knowledge of the matter.
Reuters said both sources did not believe the Trump administration — and Musk as head of the Dept. of Government Efficiency (DOGE) — specifically targeted them due to their work on Neuralink’s regulatory submissions. The report, however, quoted former FDA official, Victor Krauthamer, expressing concern over the impact the cuts could have. Krauthamer spent more than three decades at the FDA and spent time as acting director of the office that reviews human trial requests for BCIs.
“It’s intimidating to the FDA professionals who are overseeing Neuralink’s trial,” said Krauthamer. “We should be worried about the whole trial, and the protection of the people in the trial.”"
As someone who develops neurosurgical devices this really stinks.
https://www.massdevice.com/fda-medtech-r...p-layoffs/
"FDA firings have an interesting relation to Musk’s Neuralink
Reuters reports that the FDA cuts extended to some agency employees reviewing Elon Musk’s Neuralink brain-computer interface (BCI) company.
The report said the firings included around 20 people in the FDA’s office of Neurological and Physical Medicine Devices. Several of those employees worked on Neuralink and other BCI devices, the report said, citing two sources with knowledge of the matter.
Reuters said both sources did not believe the Trump administration — and Musk as head of the Dept. of Government Efficiency (DOGE) — specifically targeted them due to their work on Neuralink’s regulatory submissions. The report, however, quoted former FDA official, Victor Krauthamer, expressing concern over the impact the cuts could have. Krauthamer spent more than three decades at the FDA and spent time as acting director of the office that reviews human trial requests for BCIs.
“It’s intimidating to the FDA professionals who are overseeing Neuralink’s trial,” said Krauthamer. “We should be worried about the whole trial, and the protection of the people in the trial.”"
As someone who develops neurosurgical devices this really stinks.